Risperdal is an atypical antipsychotic approved by the U.S Food & Drug Administration to treat schizophrenia, bipolar disorder, and irritability in children with autistic disorder. Unfortunately, the medication has proven to pose serious risks to male children and adults, including gynecomastia (male chest growth) and significant weight gain. As of December 2014, 2014, court documents indicate that 1,183 claims have been filed in Pennsylvania on behalf of individuals who developed gynecomastia or other serious complications. This represents an increase of more than 100 filings in the past month. (In Re: Risperdal Litigation, Case Number 100300296).